, three previously healthy collegiate wrestlers in different states died while each was engaged in a program of rapid weight loss to qualify for competition. In the hours preceding the official weigh-in, all three wrestlers engaged in a similar rapid weight-loss regimen that promoted dehydration through perspiration and resulted in hyperthermia. The wrestlers restricted food and fluid intake and attempted to maximize sweat losses by wearing vapor-impermeable suits under cotton warm-up suits and exercising vigorously in hot environments. This report summarizes the investigation of these three cases.
Vigorous exercise and dehydration increase body temperature, which is further increased by use of vapor-impermeable suits that decrease evaporative and convective heat loss. In the three cases presented in this report, all three wrestlers used vaporimpermeable suits and exercised vigorously in hot environments. These conditions promoted dehydration and heat-related illness (3, 5, 6 ) . In all three cases, elevated sodium and urea in antemortem blood or postmortem vitreous fluid indicated clear evidence of dehydration. The exercise regimen, the elevated rectal temperature in case 2, and the rhabdomyolysis and myoglobinuria in case 3 indicate that hyperthermia may have contributed to these deaths (6, 7 ) .
Among the three wrestlers, the difference between their preseason weight and their goal weight for competition was 30 lbs (range: 25-37 lbs), or approximately 15% of total body weight. Among collegiate wrestlers, the difference between their preseason and competitive weights averages approximately 16 lbs (5 ) , or approximately 10% of total body weight (4 ) . These cases highlight the extreme extent of absolute and relative weight loss. Under such conditions, particularly when dehydration is involved, there are no established limits for safe weight loss.
To ensure fair and safe competition, wrestlers compete within defined weight categories. At the time of these deaths, existing National Collegiate Athletic Association (NCAA) guidelines recommended that the rapid weight-loss behaviors associated with these deaths be prohibited (8 ) . Using practices contrary to the guidelines, all three wrestlers, while under the supervision of athletic staff, attempted to lose unsafe amounts of weight in a short period of time. The findings in the three cases suggest that failure to follow these guidelines may have contributed to these deaths. The weight-loss behaviors reported in these three cases are common among wrestlers; however, deaths associated with weight loss in collegiate wrestling have not been reported previously (1 ) . No information is available to indicate whether the amount or rate of intentional weight loss or other conditioning practices may have changed recently among collegiate wrestlers.
As a result of these deaths, the NCAA revised the guidelines governing weight-loss practices and weigh-in procedures and added penalties for noncompliance (9 ) . The NCAA now prohibits the use of laxatives, emetics, diuretics, excessive food and fluid restriction, self-induced vomiting, hot rooms >79 F (>26 C), hot boxes, saunas, steam rooms, vapor-impermeable suits, and artificial rehydration techniques (e.g., intravenous hydration between weigh-in and competition). In addition, for this season the NCAA has added a 7-lb weight allowance to each weight class, required all wrestlers to compete only in the weight class that they were in as of January 7, and stipulated that all weigh-ins be held no more than 2 hours before the beginning of competition. The NCAA plans to reassess its wrestling policies this spring. The effectiveness of these changes should be monitored and evaluated.
The sudden deterioration and resulting deaths of previously healthy, young, welltrained athletes underscores the need to eliminate weight-control practices that emphasize extreme or rapid weight loss. To ensure safe weight-control practices, a health-care professional should identify an appropriate competition weight and specify rates and limits of allowable weight loss for each wrestler. In addition, coaches and athletes should be trained in proper weight-control strategies and work collaboratively with a health-care professional to develop and monitor a weight-control regimen. Use of intentional dehydration to lose weight should be prohibited. To monitor compliance, a practical test to assess hydration status should be explored and employed. In addition, existing surveillance systems should be strengthened to evaluate effectiveness in preventing athletic injuries, illnesses (e.g., hyperthermia and dehydration), and deaths among the 400,000 wrestlers who participate annually in the United States (10 ) . Because wrestlers have traditionally used dehydration as a means to lose weight, vigorous efforts will be necessary to ensure compliance with rules and guidelines designed to reduce health risks and the potential for death. Vaccination Coverage Levels -Continued The National Immunization Survey (NIS) is an ongoing survey that provides national estimates of vaccination coverage among children aged 19-35 months* based on data for the most recent 12 months for each of the 50 states, the District of Columbia, and 27 other selected urban areas (1, 2 ) . CDC initiated the NIS in April 1994 to monitor vaccination coverage levels as part of the Childhood Immunization Initiative (CII), a national strategy to ensure high vaccination coverage of children during the first 2 years of life (3 ). This report presents NIS findings for July 1996-June 1997, which indicate that vaccination levels among U.S. children aged 19-35 months remain the highest ever recorded. This report also includes the first annualized estimates for varicella vaccine coverage.
NIS uses a quarterly random-digit-dialed sample of telephone numbers for each survey area to collect vaccination information for all eligible children. During July 1996-June 1997, a total of 32,652 household interviews were completed, representing 33,064 children (mean: 424 children per survey area). The overall response rate for eligible households was 67% for all 78 survey areas (range: 55%-83%). For completeness and verification, vaccination data also are requested from vaccination providers. Provider data are weighted to represent the entire group of children surveyed and to account for household nonresponse, natality data, and the lower vaccination coverage levels among children in households without telephones (1, 2, 4 ) .
Compared with 1996, national vaccination coverage with all individual vaccines and the 4:3:1 † and 4:3:1:3 § series during July 1996-June 1997 remained stable at high levels, except that coverage with hepatitis B vaccine showed a small, but statistically significant, increase of 1.5% (from 81.8% to 83.3%) ( Table 1) .
The national coverage level for varicella vaccine during July 1996-June 1997 was 19% (Table 1) . During the last quarter of this reporting period (April-June 1997), national varicella vaccine coverage was 25% (Table 1 ). For July 1996-June 1997, varicella coverage levels ranged from 3% to 33% (median: 17%) among states and from 7% to 33% (median: 16%) among selected urban areas (Table 2) .
During July 1996-June 1997, estimated state-specific coverage levels for the 4:3:1 series ranged from 69% to 91% (median: 79%), and for the 4:3:1:3 series, from 67% to 88% (median: 77%) ( Table 3) . Estimated coverage levels among selected urban areas ranged from 63% to 86% (median: 77%) for the 4:3:1 series and from 61% to 85% (median: 74%) for the 4:3:1:3 series (Table 4) . Compared with 1996, there were statistically significant changes in state-specific coverage with the 4:3:1:3 series in West Virginia (from 71% to 80%) and New York (from 79% to 74%); among selected urban areas, changes were statistically significant in Marion County, Indiana (from 72% to 78%), and the District of Columbia (from 78% to 72%). During July 1996-June 1997, the coverage range for 4:3:1:3 among the states narrowed compared with 1996 (range: 67%-88% versus 63%-87%, respectively). For urban areas, the 4:3:1:3 coverage range remained virtually unchanged (61%-85% in July 1996-June 1997 versus 62%-84% in 1996) (2 ) .
Compared with 1996, the number of states and selected urban areas that met the 1996 CII coverage goal for three or more doses of hepatitis B vaccine increased from 48 to 50 and from 27 to 28, respectively. The number that met the goal for three or more doses of DTP increased from 48 to 50 states and decreased from 26 to 25 urban areas; urban areas that did not meet the goal were within 2% below the goal. The number that met the goal for three or more doses of poliovirus vaccine increased from 38 to 40 states and decreased from 17 to 13 urban areas; all remaining states and 13 of the remaining 15 urban areas had coverage levels of 85%-89%. For one or more doses of MCV, the number reaching the 1996 interim coverage goal for measles-mumpsrubella vaccine (MMR) increased from 32 to 37 states, but decreased from 19 to 18 urban areas; all the remaining states and eight of the 10 remaining urban areas had coverage levels of 85%-89%. The number that met the goal for three or more doses of Hib vaccine increased from 41 to 45 states but decreased from 19 to 18 urban areas; all remaining states and nine of the remaining 10 urban areas had coverage levels of 85%-89%. Overall, the number that met all CII vaccination coverage goals, including † Four or more doses of diphtheria and tetanus toxoids and pertussis vaccine/diphtheria and tetanus toxoids (DTP/DT), three or more doses of poliovirus vaccine, and one or more doses of measles-containing vaccine (MCV). § Four or more doses of DTP/DT, three or more doses of poliovirus vaccine, one or more doses of MCV, and three or more doses of Haemophilus influenzae type b vaccine (Hib). the goal for hepatitis B vaccine, increased from 30 to 33 states, but decreased from 14 to 11 urban areas (2 ). Editorial Note: The NIS data in this report indicate that all national coverage goals established by CII for 1996 have been met or exceeded for the vaccines routinely recommended for children. Attainment of these goals reflects the widespread implementation of the comprehensive CII strategy by public-and private-sector organizations and health-care providers at the national, state, and local levels (3 ). Coverage with hepatitis B vaccine for July 1996-June 1997 increased slightly over 1996 levels, whereas sizable increases occurred from 1994 to 1995 (from 37% to 68%) and from 1995 to 1996 (from 68% to 82%). These findings indicate that substantial effort will be required to attain the 1998 interim national goal of 90% for hepatitis B vaccine (2, 3, 5 ) .
Before the availability of varicella vaccine, approximately 4 million cases occurred each year in the United States, resulting in an annual average of 105 deaths and 4000-9000 hospitalizations. Most cases occur among children and are preventable by vaccination. In 1997, several deaths attributed to varicella among adults were associated with transmission from unvaccinated preschool-aged family members; these deaths underscore the importance of universal childhood vaccination for varicella (6 ) .
This reporting period coincided with the first 12 months since the inclusion of varicella vaccine in the recommended childhood immunization schedule in July 1996. The national coverage estimate for varicella vaccine was the lowest of all the recommended vaccines, partially because most children surveyed during this reporting period were aged >18 months before the vaccine was first recommended (2 ) . The wide variation of varicella vaccine coverage by state (from 3% to 33%; median: 16%) indicates a need for special efforts in states with lower coverage levels. The national estimates for the last quarter of this reporting period suggest an upward trend in varicella vaccination coverage. Additional increases are expected with the implementation of the extended financing of varicella vaccination by the Vaccines for Children Program (VFC), which makes available all recommended vaccines to public-and private-sector health-care providers for children who qualify (7 ). State and local public health officials should encourage more public-and private-sector providers to participate in VFC, which should be especially beneficial for uninsured children and children living below the poverty level.
In this reporting period, the 4:3:1 and 4:3:1:3 series coverage remained relatively unchanged. These findings primarily reflect relatively low coverage with the fourth dose of DTP (81%) ( Table 1) . On the basis of these data, approximately 1 million children still need one or more of the recommended doses of vaccine to be fully protected.
Although national 1996 CII coverage goals have been attained for all individual vaccines, coverage differed substantially by state and urban area, and many states and urban areas did not meet the 1996 CII goals for the individual vaccines. Moreover, 13 states and 10 urban areas have not achieved the 1995 interim goal for MCV (90%); two urban areas have not achieved the 1995 goal for poliovirus vaccine (85%); and one urban area has not achieved the 1995 goal for Hib vaccine (85%) (2 ) . Vaccination providers in these areas should intensify their efforts, so that children are equally well protected throughout the United States.
The addition of new vaccines (e.g., varicella vaccine) to the existing vaccination schedule presents a challenge to the vaccine-delivery system that must be met before the full benefits of new vaccine technology can be realized. The achievement of the 1996 goals during July 1996-June 1997 was a major milestone in the effort to control vaccine-preventable diseases; however, this reporting period indicated only one net gain compared with 1996: a modest increase in hepatitis B vaccine coverage. Furthermore, except for varicella vaccine, no other meaningful increases were detected for the last quarter of this reporting period, which may suggest a leveling off in vaccination coverage. To overcome this apparent leveling in coverage, and to attain the year 2000 objective of 90% coverage with a complete series, vaccination providers must become even more efficient and effective in ensuring full protection of children. Each day, an estimated 11,000 children are born in the United States, and all must receive 12-16 doses of vaccine before the second birthday to be fully vaccinated. Achievement of the 1996 goals demonstrates that reaching high coverage levels is possible but does not ensure such coverage in the future. Meeting these and other goals at the national, state, and local levels requires a fully functional vaccination delivery system, which remains incomplete in 1998. Important components of this system are state-and community-based computerized vaccination registries, which include all children from birth and can identify children in need of vaccines and recall them for missed vaccinations (8 ); ongoing quality assurance and information * Four or more doses of diphtheria and tetanus toxoids and pertussis vaccine/diphtheria and tetanus toxoids (DTP/DT), three or more doses of poliovirus vaccine, and one or more doses of measles-containing vaccine (MCV). † Four or more doses of DTP/DT, three or more doses of poliovirus vaccine, one or more doses of MCV, and three or more doses of Haemophilus influenzae type b vaccine (Hib). § Children in this period were born during August 1993-November 1995. ¶ Confidence interval. 
Progress Toward Poliomyelitis EradicationTurkey, 1994-1997
Poliomyelitis Eradication -Continued In 1989, as part of the global poliomyelitis eradication initiative, Turkey adopted the goal of eliminating polio by 2000; since then, substantial progress has been made toward achieving this objective. Turkey is a priority country for the global polio eradication initiative because of its large population (1996 population: 60 million), strategic location between Europe and Asia, and proximity to countries with endemic polio. This report summarizes progress during 1994-1997 in Turkey toward implementing the four polio eradication strategies recommended by the World Health Organization (WHO) (1 ), reviews the cluster of polio cases in 1997, and suggests that recent poliovirus transmission might have resulted from suboptimal vaccination coverage in some areas of Turkey.
Routine Vaccination Coverage. During 1989-1994, reported rates of vaccination coverage with three or more doses of oral poliovirus vaccine (OPV3) in children by age 1 year provided by the routine vaccination program ranged from 74% to 81% (Figure 1 ). OPV3 coverage declined to 66% in 1995 because of problems with vaccine procurement and increased to 83% in 1996. Based on preliminary data, in 1997 the reported vaccination coverage rate decreased to 75%. Rates differed substantially among the 80 provinces. Eighteen provinces, composing 15% of the total population and located primarily in southeastern and eastern Turkey, reported annual coverage rates of <80% (range: 8%-78%) for 1994-1997 ( Figure 2 ). To improve routine vaccination coverage levels, vaccination activities with OPV, diphtheria-tetanus-pertussis vaccine, and measles vaccine were intensified in the 19 provinces in which coverage rates were low in 1996. As a result, OPV3 coverage among children by age 1 year in the targeted provinces increased from 46% to 60% by the end of 1996.
National Immunization Days. Turkey conducted three National Immunization Days (NIDs)* in 1995, 1996, and 1997 as part of Operation MECACAR (Mediterranean, Caucasus, and Central Asian Republics) (2, 3 ) , in which 18 geographically contiguous countries in Asia, the Middle East, and Europe synchronized NIDs. NID coverage differed by province and was <80% in six to 11 provinces during 1995-1997. During this period, routine OPV3 coverage and NID coverage for any round did not reach 80% in seven provinces. In 1997, 73% of OPV doses given during NIDs were administered during house-to-house visits.
Surveillance. Acute flaccid paralysis (AFP) surveillance was initiated in Turkey in 1989. Case-based information is passively reported by the provincial health departments to the Ministry of Health in Ankara. Stool specimens obtained from patients with AFP are evaluated at the national reference laboratory in Ankara. The national polio laboratory processes stool specimens to isolate poliovirus and identify poliovirus serotypes. Poliovirus isolates are sent to the regional reference laboratory in the Netherlands for intratypic differentiation of poliovirus as wild or vaccine-related; aliquots of primary stool specimens are shipped for confirmatory testing (4 ) .
In 1997, WHO began accrediting national polio laboratories in Europe to be formally recognized as members of the Global Laboratory Network. Accreditation includes a proficiency test panel of prepared specimens, with a target score of 80% (4 ). The Turkish national polio laboratory achieved a perfect score of 100% in this proficiency testing. Full accreditation by WHO, anticipated in 1998, will require additional technical improvements.
An important performance indicator for adequate AFP surveillance is the annual reported rate of nonpolio AFP cases per 100,000 children aged <15 years (target: ≥1 case per 100,000) (1 ). In Turkey, the nonpolio AFP rate was 0.3 in 1994, 0.5 in 1995, 0.4 in 1996, and 0.6 in 1997 (preliminary data). The increase in 1997 occurred primarily because a larger number of provinces (26 in 1997 versus 10 in 1996) achieved a rate of ≥1 case. However, 39 (49%) of 80 provinces, constituting one third of the total population, did not report AFP cases. Four of these provinces are small, and an AFP case would not be expected every year; however, the remaining 35 provinces would be expected to report at least 63 nonpolio AFP cases annually.
The second important surveillance quality indicator is the proportion of patients with AFP from whom two adequate stool specimens are obtained. † In Turkey, the proportion of AFP cases for which two adequate stool specimens were evaluated was 16% in 1994, 45% in 1995, 36% in 1996, and 65% in 1997 (preliminary data).
*Mass campaigns over a short period (days to weeks) in which two doses of OPV are administered to all children in the target age group, regardless of previous vaccination history, with an interval of 4-6 weeks between doses. † Two stool specimens collected at an interval of at least 24 hours within 14 days of onset of paralysis. WHO recommends that ≥80% of patients with AFP should have two adequate specimens collected (1 ).
Other Supplementary Immunization Activities. Before conducting NIDs, vaccination campaigns were conducted in 1994 in two provinces following the detection of wild polioviruses. During these campaigns, in which children aged <5 years were targeted for vaccination regardless of their previous vaccination status, vaccination coverage rates were ≥94%.
In October and November 1997, Turkey conducted two rounds of "mopping-up" vaccination § in 28 provinces with either low routine vaccination coverage (<80% OPV3 coverage since 1995), poor AFP surveillance (i.e., no reporting of cases since 1995), or increased risk for poliovirus importation from neighboring countries with endemic polio. Reported coverage in the first and second rounds of the mopping-up campaign, targeting 20% of the total population, was 84% and 84%, respectively. However, supplemental vaccination coverage for the first round was <80% in seven (25%) participating provinces.
Polio Incidence
In Turkey, the number of reported polio cases confirmed by the standard WHO clinical case definition ¶ has decreased under conditions of improved surveillance since 1994 (32 in 1994, 32 in 1995, and 19 in 1996) (Figure 1 ). In 1994, wild poliovirus type 1 (P1) was isolated from seven patients located in five provinces of the southeastern and western regions of the country. Two distinct genotypes of P1 were identified by genomic sequencing analysis. In 1995, wild poliovirus type 3 (P3) was isolated in a northwestern province. In 1996, no wild poliovirus was isolated.
In 1997, a total of 141 AFP cases were reported from Turkey; six AFP cases were confirmed as polio by wild P1 isolation, the first wild P1 isolated since 1994. The virologically confirmed cases had onset of paralysis during July 23-October 10, 1997; these cases occurred in patients from Mardin province (Figure 2 ). All six patients were aged 9 months-2 years; four patients were unvaccinated, and two had received only one dose of OPV. Genomic sequencing of the viral isolates from the 1997 cluster indicated a distinct relation with wild P1 isolates obtained from eastern Turkey in 1994. Routine vaccination coverage in Mardin has been <50% since 1994, although reported coverage was ≥78% for all NID rounds. Coverage rates for the two rounds of moppingup vaccination in Mardin in 1997 were 80% and 65%, respectively. No additional polio cases have been detected from Mardin or other provinces in Turkey. Editorial Note: Turkey has made substantial progress in polio eradication activities since 1989. The number of reported polio cases declined substantially after implementation of NIDs, and no wild polioviruses were isolated from June 1995 through June 1997. During July-October 1997, a cluster of virologically confirmed cases occurred in § Focal mass campaign in high-risk areas over a short period (days to weeks) in which two doses of OPV are administered during house-to-house visits to all children in the target age group, regardless of previous vaccination history, with an interval of 4-6 weeks between doses. ¶ A confirmed case of polio is defined as AFP and at least one of the following: 1) laboratoryconfirmed wild poliovirus infection, 2) residual paralysis at 60 days, 3) death, or 4) no followup investigation at 60 days.
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one province. This cluster emphasizes the importance of establishing effective AFP surveillance, maintaining high routine vaccination coverage, achieving high levels of coverage during NIDs, and implementing mopping-up campaigns in high-risk areas to limit poliovirus transmission. Wild poliovirus identified in this cluster was either indigenous virus, which may have continued to circulate undetected because of limited AFP surveillance, or wild virus originating from a neighboring country in which polio is endemic (5 ) . The source of the wild poliovirus in this cluster could not be determined, and no virus isolates were available from recent cases in neighboring countries to enable molecular epidemiologic analysis of poliovirus circulation. As a result of this cluster and the outcome of past vaccination efforts, the Ministry of Health has strengthened all aspects of the national polio eradication effort. NIDs will be conducted in the spring of 1998, and mopping-up vaccination campaigns are being considered. Efforts are under way to improve routine vaccination coverage in the geographic area where wild polioviruses were detected and in all other provinces where coverage has been consistently low.
Improving AFP surveillance in all provinces is a high priority. Efforts to improve AFP surveillance include 1) additional training of public health staff at the provincial and district levels; 2) establishing and maintaining active surveillance by regularly reviewing hospital records and contacting health-care providers in major clinics and hospitals; 3) establishing a strong relation with national and local organizations of health-care providers who are likely to treat patients with AFP; 4) augmenting laboratory equipment, supplies, and procedures; and 5) improving coordination between the laboratory and surveillance staff.
In 1997, a year with a historically low number of reported cases in the European Region of WHO, Turkey was the only country in which wild poliovirus transmission was detected (3 ). The European Region can be certified as free of indigenous wild poliovirus transmission only after no wild poliovirus has been detected for at least 3 consecutive years in the presence of high-quality AFP surveillance. The WHO Regional Offices for Europe and the Eastern Mediterranean continue to coordinate polio eradication activities that began in 1995 with the synchronized mass vaccination activities of Operation MECACAR (3, 5 ) and will include simultaneous "mopping-up" and catch-up vaccination campaigns. NIDs will be coordinated between several bordering countries in the Middle East, Caucasus, and Central Asian Republics during Operation MECACAR Plus, which will be held during March-May 1998. National governments are working in cooperation with the major partner agencies contributing to the polio-eradication initiative (e. - ----2  -74  164  -156  22  Ark.  ------21  25  -11  1  La.  ----2  -46  62  ---Okla.  ------7  20  U  14  21  Tex.  -------57  U  131  -MOUNTAIN  7  9  --7  9  26  24  22  18  8  Mont. - PACIFIC  9  5  5  5  16  53  18  38  252  449  13  Wash.  -1  ----1  -U  28  -Oreg.  ---2  3  2  1  1  U  14  -Calif.  9  3  5  3  13  51  16  37  239  371  11  Alaska  --------4  11  2  Hawaii  -1  ------9 25 - .  15  2  224  185  30  20  ------Utah  2  1  25  118  8  11  ------Nev.  5  2  22  32  9  5  U  -U  ---PACIFIC  9  22  417  897  147  184  -----5  Wash.  --42  26  14  3  ------Oreg.  8  5  41  57  12  14  ------Calif.  -15  331  799  119  161  -----2  Alaska  ---4  1  3  ------Hawaii  1  2  3  11  1  3  -----3   Guam  -----1  U  -U  ---P.R.  ---22  8  55  ------V.I. - 
